Cyfuse Biomedical K.K Past Earnings Performance

Past criteria checks 0/6

Cyfuse Biomedical K.K's earnings have been declining at an average annual rate of -30.4%, while the Life Sciences industry saw earnings growing at 24.8% annually. Revenues have been declining at an average rate of 127.2% per year.

Key information

-30.4%

Earnings growth rate

41.0%

EPS growth rate

Life Sciences Industry Growth32.0%
Revenue growth rate-127.2%
Return on equity-26.4%
Net Margin-1,239.7%
Next Earnings Update14 Feb 2025

Recent past performance updates

Recent updates

Is Cyfuse Biomedical K.K (TSE:4892) Using Too Much Debt?

Dec 04
Is Cyfuse Biomedical K.K (TSE:4892) Using Too Much Debt?

Is Cyfuse Biomedical K.K (TSE:4892) Weighed On By Its Debt Load?

Jul 16
Is Cyfuse Biomedical K.K (TSE:4892) Weighed On By Its Debt Load?

Is Cyfuse Biomedical K.K (TSE:4892) A Risky Investment?

Mar 01
Is Cyfuse Biomedical K.K (TSE:4892) A Risky Investment?

Revenue & Expenses Breakdown

How Cyfuse Biomedical K.K makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

TSE:4892 Revenue, expenses and earnings (JPY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 2458-719492375
30 Jun 2461-672434375
31 Mar 2464-645411375
31 Dec 2361-589351375
30 Sep 2363-735421303
30 Jun 2360-723411303
31 Mar 23215-584368303
31 Dec 22374-473346303
31 Dec 217081425000
31 Dec 20137-3294390

Quality Earnings: 4892 is currently unprofitable.

Growing Profit Margin: 4892 is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 4892 is unprofitable, and losses have increased over the past 5 years at a rate of 30.4% per year.

Accelerating Growth: Unable to compare 4892's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 4892 is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (1.4%).


Return on Equity

High ROE: 4892 has a negative Return on Equity (-26.39%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/03 04:46
End of Day Share Price 2024/12/30 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Cyfuse Biomedical K.K. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution